Immunic grants CMO options on 300,000 shares

Immunic, Inc. granted Chief Medical Officer Michael A. Panzara a stock option covering 300,000 shares of common stock.

Rhea-AI Filing Summary

Immunic, Inc. granted Chief Medical Officer Michael A. Panzara a stock option covering 300,000 shares of common stock. The option has an exercise price of $8.80 per share and expires on April 24, 2036, representing a compensation-related award rather than an open-market trade.

According to the vesting terms, 50% of the underlying 300,000 shares will vest on April 24, 2027, and the remaining 50% will vest in 24 equal monthly installments, as long as he remains an employee of Immunic in good standing through each vesting date.

Insider Trade Summary

Grant/Award: 300,000 shares

Grant/Award 1 txn

Insider Panzara Michael A.

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option	300,000	$0.00	$0.00

Holdings After Transaction: Stock Option — 300,000 contracts (Direct)

Footnotes (1)

1. F1. The options disclosed on this Form 4 are time vested; 50 percent of the shares underlying the options awarded to the Reporting Person will vest on April 24, 2027, and 50 percent of them will vest in 24 equal monthly installments, subject to the Reporting Person remaining an employee of Immunic, Inc. in good standing through the relevant vesting date.

Key Figures

Stock options granted: 300,000 options Exercise price: $8.80 per share Expiration date: April 24, 2036 +3 more

6 metrics

Stock options granted 300,000 options Grant to Chief Medical Officer on April 24, 2026

Exercise price $8.80 per share Exercise price of granted stock options

Expiration date April 24, 2036 Option expiration for the 300,000-share grant

Post-grant derivative holdings 300,000 options Total options held following the reported transaction

Cliff vesting portion 50% of 300,000 shares Vests on April 24, 2027, subject to continued employment

Remaining vesting schedule 50% over 24 months Vests in 24 equal monthly installments after April 24, 2027

Key Terms

Stock Option, time vested, vesting date, exercise price

4 terms

Stock Option financial

"security_title: Stock Option; underlying security is Common Stock"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

time vested financial

"The options disclosed on this Form 4 are time vested; 50 percent of the shares..."

vesting date financial

"...remaining an employee of Immunic, Inc. in good standing through the relevant vesting date."

exercise price financial

"conversion_or_exercise_price: 8.8000 per share for the option grant"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Immunic (IMUX) disclose in this Form 4 filing?

Immunic reported a grant of stock options to Chief Medical Officer Michael A. Panzara. The award covers 300,000 shares of common stock and is structured as time-vested equity compensation rather than an open-market purchase or sale of existing shares.

How many Immunic (IMUX) shares are covered by the new stock option grant?

The stock option grant covers 300,000 shares of Immunic common stock. This represents the total number of shares underlying the award, all subject to vesting conditions before the options can be fully exercised for common shares.

What is the exercise price of the Immunic (IMUX) stock options granted?

The stock options granted to Michael A. Panzara have an exercise price of $8.80 per share. This is the fixed price at which he may purchase Immunic common stock upon exercising vested portions of the option, subject to the specified vesting schedule.

When do the granted Immunic (IMUX) stock options vest for the CMO?

The options are time vested. Half of the 300,000 underlying shares vest on April 24, 2027, while the remaining half vest in 24 equal monthly installments, contingent on his continued employment with Immunic in good standing at each vesting date.

When do the newly granted Immunic (IMUX) stock options expire?

The stock options granted to the Chief Medical Officer expire on April 24, 2036. After this expiration date, any unexercised vested portion of the options can no longer be used to purchase Immunic common stock at the $8.80 per share exercise price.

Is this Immunic (IMUX) Form 4 filing about buying or selling shares on the market?

No, the Form 4 reflects a grant of stock options as compensation, not a market trade. It records an acquisition of derivative securities that may later be exercised into common shares, subject to vesting conditions and the specified expiration date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/29/2026 - 07:14 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Panzara Michael A.

(Last) (First) (Middle)

1200 AVENUE OF THE AMERICAS, SUITE 200

(Street)

NEW YORK NEW YORK 10036

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
IMMUNIC, INC. [ IMUX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$8.8	04/24/2026		A		300,000		(1)	04/24/2036	Common Stock	300,000	$0.00	300,000	D

Explanation of Responses:

1. The options disclosed on this Form 4 are time vested; 50 percent of the shares underlying the options awarded to the Reporting Person will vest on April 24, 2027, and 50 percent of them will vest in 24 equal monthly installments, subject to the Reporting Person remaining an employee of Immunic, Inc. in good standing through the relevant vesting date.

	/s/ Grant Levine, attorney-in-fact	04/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)